Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ablation combo may keep AFib at bay longer

NCT ID NCT03057548

Disease control Sponsor: Arash Aryana, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding ablation of the left atrial posterior wall to standard pulmonary vein isolation reduces the return of atrial fibrillation in people with persistent AF. A total of 110 adults having their first catheter ablation took part. The goal was to see if the combined procedure leads to fewer arrhythmia episodes one year later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation procedure
What this could lead to
If successful, this combined ablation approach could offer a more effective way to control persistent atrial fibrillation and reduce the chance of it coming back.
What could go wrong
This is a completed trial with 110 participants, so results are limited in size. The procedure carries risks like bleeding or heart complications, and the added ablation may not provide extra benefit over standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Feb 2017

Finished

May 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females with an age \>18 years undergoing a first-time catheter ablation of AF; prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial flutter) is permitted * All patients must understand the requirements of the study and be willing to comply with the post-study follow-up requirements * Patients must be in AF on the day of the procedure Exclusion Criteria: * Any reversible cause of AF (post-operative, thyroid disorder, etc) * Patients with cerebral ischemic events (stroke or transient ischemic attack), myocardial infarction or unstable angina in the previous 2 months * Patients with any corrected or uncorrected congenital heart disease * Patients with a history of hypertrophic cardiomyopathy * Patients with cardiomyopathy and a left ventricular ejection fraction \<35% * Congestive heart failure, class IV * Women who are known to be pregnant or have had a positive β-Human Chorionic Gonadotropin (β-HCG) test 7 days prior to procedure * Patients whose life expectancy is \<1 year * History of left-sided left atrial ablation (catheter or surgically-based) * Mental impairment precluding the patient from providing informed consent or completing appropriate follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation chronic Persistent atrial fibrillation

Contacts and locations

Locations

  • Heart Center, Japan Red Cross Yokohama-city Bay Hospital

    Yokohama, Japan

  • Mercy General Hospital and Dignity Health Heart and Vascular Institute

    Sacramento, California, 95819, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.